Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 20, No 11 (2022) > Article

DOI: 10.14704/nq.2022.20.11.NQ66247

REGIONAL CURRENT PROBLEMS AND SOLUTIONS OF BRONCHIAL ASTHMA (according to the results of a special epidemiological study)

Mamasoliev N.S., Kholikova N.A., Khakimov D.M., Kurbonova R. R., Shamsiddinova A.S., Ergashev E.E., Kalandarov D.M.

Abstract

Considerable clinical progress has been made around bronchial asthma (BA). At the same time, there are many unresolved issues. Until now, there is no cure, there is a fear of taking drugs for life, and it will continue to increase in the coming years, and by 2025, the number of patients with BA will reach 450 million. Its loss is high: • it is one of every 250 deaths in the world; • annual costs for it are from 17.7 billion euros (in the European Union) to 20 billion dollars (in the United States) [5,14]. Unacceptable epidemiological situation regarding BA has been maintained in Uzbekistan for several years. For example, in some of its regions, every fifth person has this disease. About 82.0% of the disease is diagnosed late, and severe BA has been reported to increase more than 10-fold with increasing age [2, 4, 10]. Life-saving drugs are inconsistently and ineffectively used in different regions, their pharmacoepidemiology is not sufficiently studied in patients with BA, and, on top of that, negative side effects are increasing: up to 15.1%, adverse drug reactions occur and are simple to eliminate. the hospital costs up to 5.6 million dollars per year [9, 11, 18].

Keywords

Full Text

PDF

References

?>